CD8A and diffuse large B-cell lymphoma: This study evaluates the prognostic value of AMC, TAMs (CD163), and TILs (CD8) on two-year EFS in DLBCL patients treated with R-CHOP.<h4>Methods</h4>A retrospective cohort study of 108 DLBCL patients treated from January 2014 to March 2021 was conducted.